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Abstract: Dementia is one of the most important neurological disorders in the elderly. Aging 
is associated with a large increase in the prevalence and incidence of degenerative (Alzheimer’s 
disease) and vascular dementia, leading to a devastating loss of autonomy. In view of the 
increasing longevity of populations worldwide, prevention of dementia has turned into a major 
public health challenge. In the past decade, several vascular risk factors have been found to be 
associated with vascular dementia but also Alzheimer’s disease. Some longitudinal studies, have 
found signiﬁ  cant associations between hypertension, diabetus mellitus, and metabolic syndrome, 
assessed at middle age, and dementia. Studies assessing the link between hypercholesterolemia, 
atrial ﬁ  brillation, smoking, and dementia have given more conﬂ  icting results. Furthermore, some 
studies have highlighted the possible protective effect of antihypertensive therapy on cognition 
and some trials are evaluating the effects of statins and treatments for insulin resistance. Vascular 
risk factors and their treatments are a promising avenue of research for prevention of dementia, 
and further long-term, placebo-controlled, randomized studies, need to be performed.
Keywords: dementia, hypertension, diabetus mellitus, hypercholesterolemia, metabolic 
syndrome
Introduction
Dementia is one of the most important neurological disorders in the elderly. As 
life expectancy increases, the worldwide number of demented patients is projected 
to grow from 24.3 million in 2001 to 81.1 million in 2040 (Ferri et al 2005). In 
occidental countries, the most common forms of dementia are Alzheimer’s disease 
(AD) and vascular dementia (Vad), with respective frequencies of 70% and 15% 
among all dementias (Whitehouse et al 1997). AD is the most common primary 
neurodegenerative disorder in the elderly. Its neuropathological hallmarks are 
intraneuronal protein clusters of hyperphosphorylated tau protein (neuroﬁ  brillary 
tangles) and extracellular Aβ protein aggregation. This aggregation is the result of 
an abnormal amyloid precursor protein (APP) cleavage by β- and γ-secretases and 
initiates a pathogenic, self-perpetuating cascade ultimately leading to neuronal loss 
and dementia (Cummings et al 2004). In this context, the prevention of cognitive 
disorders represents a major challenge in the coming years. The identiﬁ  cation of 
the risk factors for these debilitating conditions must be a priority in order to deﬁ  ne 
the best approach for early prevention.
In the past decade, several vascular risk factors have been found to be associ-
ated with not only Vad but also, surprisingly, AD. We propose a review of these 
epidemiological associations and their underlying pathophysiological mechanisms 
(apolipoprotein E, hypertension, diabetus mellitus, obesity and metabolic syndrome, 
hypercholesterolemia, atrial ﬁ  brillation, smoking, atherosclerosis). Studies included in 
this non-systematic review were identiﬁ  ed by searches of Medline and were restricted 
to papers published in English. The search terms were: apolipoprotein E, hypertension, 
diabetus mellitus, obesity and metabolic syndrome, hypercholesterolemia, atrial ﬁ  bril-
lation, smoking, atherosclerosis, heart failure, coronary heart disease AND Alzheimer’s Vascular Health and Risk Management 2008:4(2) 364
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disease OR dementia OR cognitive decline. Some relevant 
review articles were taken into account and their bibliogra-
phies were screened. Some original case-control, population-
based, and intervention studies were included.
Apolipoprotein E genotype 
and cognitive decline
Numerous genes related to vascular disease have been shown 
to increase susceptibility for sporadic AD (Panza et al 2004). 
Among them, apolipoprotein E (Apo E), which occurs in 
three common alleles (ε2, ε3, ε4), is the best documented. 
The Apo E protein is one of the major constituents in very 
low-density lipoproteins and plays a key role in the transport 
of cholesterol among various cells of the body. The ApoE ε4 
allele is known to be associated with coronary artery disease 
and the development of atherosclerosis (Davignon et al 
1988; Eichner et al 2002). This association is presumably 
related to the higher levels of total cholesterol, low density 
lipoprotein cholesterol (LDL-C) and apolipoprotein B in 
subjects homozygous for the APoE ε4 genotype than in those 
carrying ε2 or ε3.
Epidemiological studies have found an association 
between the ε4 allele of ApoE and familial and sporadic 
late-onset AD (Saunders et al 1993). Furthermore, ApoE ε4 
is associated with a younger onset of AD in a dose-dependent 
manner (Blacker et al 1997). Similarly, the Apo E genotype 
seems to predict the rate of cognitive decline in AD, in a dose-
dependent relationship with the ApoE ε4 allele (Martins et al 
2005). Mechanisms which could explain the effects of ApoE 
on the brain of AD subjects are still unclear. They include 
isoform speciﬁ  c toxicity, ApoE ε4- mediated amyloid aggrega-
tion, ApoE ε4- mediated tau hyperphosphorylation, and iso-
form-driven ApoE concentration changes (Panza et al 2006). 
ApoE could also modulate the distribution and metabolism of 
cholesterol in neuronal membranes in an isoform-dependent 
manner, which may be relevant to Apo E-related pathogenic 
effects and the development of AD (Yanasigawa 2002).
Hypertension and cognitive decline
The relationship between cognitive function and blood 
pressure has been the subject of numerous conﬂ  icts in the 
literature. The results of epidemiological studies vary with 
the methodology used. Cross-sectional studies have found 
not only positive (Starr et al 1993; Seux et al 1998) but also 
negative (Farmer et al 1987; Scherr et al 1991) correlations 
between arterial hypertension and cognitive impairment. 
Longitudinal studies are more informative since they evaluate 
the effect of “chronic” hypertension on cognitive function. 
Most of them indicate a positive relationship between the 
presence of hypertension in midlife and the onset of cognitive 
decline 15–20 years later (Table 1). Skoog et al (1996) 
have demonstrated that blood pressure values measured at 
70 years old were higher in patients developing dementia 
between the ages of 79 and 85 years than in non-demented 
subjects. Conversely, in the years preceding the onset of 
dementia, their blood pressures became identical to or less 
than those of patients who did not develop dementia. Others 
studies have observed a similar decrease in blood pressure in 
patients with AD (Hanon et al 2005b; Verghese et al 2003). 
Guo et al (1996) reported that blood pressure was lower in 
individuals over 75 years old with AD compared to patients 
without dementia and that blood pressure levels decreased 
with increasing severity of dementia. The reason for the 
decrease in blood pressure in patients with dementia has not 
been fully clariﬁ  ed. Whether the blood pressure decline is 
a cause or an effect of AD is not known. Physical inactivity 
in those afﬂ  icted by advancing mental deterioration as well 
as body mass and metabolic changes may all play a role. 
Finally, a recent study including 700 patients with AD found 
a signiﬁ  cant association between hypertension and increased 
cognitive decline over a 6-month period (odds ratio [OR] = 
1.6 [95% CI = 1.0–2.7]) (Bellew et al 2004).
To conclude, the connection between blood pressure and 
cognitive functions is more complex than a simple linear 
relationship. Chronic hypertension predisposes to cognitive 
decline and the development of dementia, but a decrease in 
blood pressure can be observed in the late interval preceding 
the onset of dementia and afterward.
The role of lowering blood pressure for the prevention 
of cognitive decline and dementia is of central importance 
and has been assessed in both non-randomized studies and 
several randomized clinical trials.
Non-randomized studies have yielded divergent results 
concerning the effect of antihypertensive drugs on cogni-
tive functions. A negative effect of antihypertensive drugs 
on cognitive functions was suspected (Heckbert et al 1997; 
Maxwell et al 1999). Instead, Guo et al (1999) have shown 
a signiﬁ  cant reduction in the risk of dementia as a result of 
antihypertensive treatment (relative risk [RR] of 0.7, 95% 
CI = 0.6–1.0). In the HOPE study (Starr et al 1996), cogni-
tive improvement was seen in subjects treated with diuretics 
or angiotensin converting enzyme inhibitors who had the 
greatest drop in blood pressure. Moreover, in the EVA cohort 
(Tzourio et al 1999), the risk of cognitive decline after 4 
years of follow up was signiﬁ  cantly lower in hypertensive 
subjects who received treatment compared to untreated Vascular Health and Risk Management 2008:4(2) 365
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hypertensive subjects (1.9 [95% CI = 0.8–4.4] versus 4.3 
[95% CI = 2.1–8.8]). Similarly, a study of 1617 elderly 
African-American subjects followed for 5 years, indicated 
a signiﬁ  cant 38% decrease in cognitive decline in treated 
hypertensive subjects compared with untreated subjects (OR 
= 0.62, 95% CI = 0.45–0.84) (Murray et al 2002). Moreover, 
a recent study found that in a sample of 1241 elderly patients, 
the odds ratio for AD was 0.58 (95% CI = 0.42–0.81) in 
treated compared with untreated hypertensive patients 
(Hanon et al 2006). Lastly, the recent Cache County Study 
performed in 3,308 people (Mean age 75 years), followed up 
3 years, indicated a signiﬁ  cant reduction of the risk of AD 
from 36% (OR = 0.64, 95% CI = 0.41–0.98) (Khatchaturian 
et al 2006). Moreover, data from the Honolulu Asia Aging 
Study showed that the duration of antihypertensive therapy 
also mattered: For each additional year of treatment, there 
was a reduction in the risk of dementia incidence (hazard 
ratio [HR] = 0.94, 95% CI = 0.89–0.99) (Peila et al 2006)
By deﬁ  nition, however, observational studies are sub-
ject to bias, and randomized, placebo-controlled studies 
are necessary to investigate the relationship between 
antihypertensive treatment and cognitive functions.
Six large randomized placebo-controlled trials have 
evaluated the effects of antihypertensive drugs on cognitive 
functions. Their results are summarized in Table 2.
In the MRC project (Prince et al 1996), a subgroup of 2584 
elderly subjects followed for 54 months showed no difference 
in neuropsychometric tests in the treated group (Diuretic or 
β-blocker) compared to the placebo group. In this study, how-
ever, the evaluation of cognitive functions was insufﬁ  ciently 
detailed and the 54-month follow up period may have been 
too short to detect a difference between the 2 groups.
In the SHEP study (SHEP Cooperative research group 
1991) the incidence of dementia was not statistically different 
in the group receiving active treatment with diuretic and/or 
β-blocker (1.6%) compared to the group receiving placebo 
(1.9%), after 5 years of follow-up, although it was slightly 
lower in the ﬁ  rst group. In this study, however, differential 
dropout biased the cognitive evaluations and may have 
obscured the assessment of a preventive effect of treatment 
on cognitive decline (Di Bari et al 2001).
Table 1 Blood pressure (BP) and cognitive decline or dementia. Longitudinal studies
References na Age at baseline  Follow up  Outcomes
(years) (years)
Elias 1993 1702 55–88 12–14 Positive correlation between BP and cognitive decline
Launer 1995 3735 50 20–28 Positive correlation between BP and cognitive decline
Yoshikate 1995 828 74 7 Positive correlation between BP and vascular dementia
Skoog 1996 382 70 9–15 Positive correlation between BP and dementia
(Alzheimer’s and vascular types)
Starr 1997 603  69 4 Positive correlation between BP and cognitive decline
Kilander 1998a 999 50 20 Positive correlation between BP and cognitive decline
Swan 1998a,b 717 45 25–30 Positive correlation between BP and cognitive decline
Tzourio 1999 1373 59–71 4 Positive correlation between BP and cognitive decline
RR = 2.8 (95% CI = 1.6–5.0)
Launer 2000 3703 50 25 Positive correlation between BP and dementia 
(Alzheimer’s and vascular types) 
RR = 4.8 (95% CI = 2.0–11.0)
Knopman 2001 10963 47–70 6 Positive correlation between BP and cognitive decline
Kivipelto 2001 1449 53 21 Positive correlation between BP and AD
OR = 2.1 (95% CI = 1.0–4.3)
Qiu 2003 1270 81 4.7 Positive correlation between pulse pressure and AD
OR = 2.1 (95% CI = 1.0–4.3)
Reinprecht 2003 186 68 13 Positive correlation between BP and cognitive decline
Piguet 2003 377  75 6 Positive correlation between BP and cognitive decline
Whitmer 2005 8845 40–44 30 Positive correlation between BP and dementia
OR = 2.1 (95% CI = 1.0–4.3)
Okumiya 1997 155 78 3 J curve between BP and cognitive decline
Glynn et al 1999 2068 65–102 6 J curve between BP and cognitive decline
Bohannon 2002 4136 65–105 3 J curve between BP and cognitive decline
Guo et al 1997 1736 75–101 3 Negative correlation between BP and cognitive decline
Zhu et al 1998 924  75 3 Negative correlation between BP and cognitive decline
Verghese et al 2003 488 79 6.7 Negative correlation between BP and AD
Morris et al 2001 634  65 13 No correlation between BP and AD
Freitag et al 2006 2505 57 5.1 No corrrelation between pulse pressure and AD
an = numbers of subjects at inclusion.
Abbreviations:   AD,   Alzheimer’s disease; OR, odds ratio; BP, blood pressure; RR, relative risk.Vascular Health and Risk Management 2008:4(2) 366
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On the other hand, the Vascular Dementia project included 
in the SYST-EUR study (Forette et al 1998) demonstrated 
for the ﬁ  rst time a reduction in the incidence of dementia 
with antihypertensive treatment. The study was conducted 
over 2 years in patients with isolated systolic hypertension 
who were at least 60 years old, randomized to receive the 
active treatment (n = 1238) or placebo (n = 1180). The active 
treatment was a calcium channel blocker (nitrendipine), pos-
sibly combined with an ACE-inhibitor (enalapril) and/or a 
diuretic (hydrochlorothiazide). The incidence of dementia 
was reduced by 50% in the active treatment group compared 
with the placebo group (p = 0.05). These ﬁ  ndings were based 
on only 32 incident cases. Nevertheless, the incidence of AD 
was reduced as well as the incidence of vascular or mixed 
dementia.
After the double-blind, placebo-controlled period, all 
patients withdrawing from double-blind were invited to 
continue or start the study antihypertensive treatment for a 
median period of 2 years (SYST-EUR 2) (Forette et al 2002). 
The incidence of dementia was updated in patients treated 
since randomisation (4 years) compared to patients who were 
actively treated only since the end of the double blind period 
(2 years). After 4 years, there was still a signiﬁ  cant difference 
in blood pressure between the two groups. Compared with 
the controls, long-term antihypertensive therapy reduced the 
incidence of dementia by 55% from 7.4 to 3.3 cases per 1000 
patient-years (p   0.001). Both types of dementia (AD and 
Vad or mixed dementia) were reduced.
Dementia and cognitive decline were secondary outcomes 
of the placebo-controlled trial PROGRESS (Tzourio et al 
2003). Treatment consisted of perindopril possibly combined 
with indapamide or a matching placebo. After 4 years of 
follow up, active treatment signiﬁ  cantly reduced the risk 
of cognitive decline by 19% in the whole population. The 
risk of dementia was reduced by 12% (95% CI = −8% to 
28%) in the active treatment-group and signiﬁ  cantly by 
34% in patients with recurrent stroke. Similarly, in patients 
receiving the combination therapy, the risk of dementia was 
signiﬁ  cantly reduced by 23% (95% CI = 0%–41%).
Data from the HOPE study (Bosch et al 2002) of 9297 
patients with vascular disease or diabetes and an additional 
vascular risk factor followed over 4.5 years, have demon-
strated a signiﬁ  cant 41% reduction in cognitive decline 
associated with stroke in the ACE inhibitor group (ramipril 
2.5–10 mg) compared to placebo.
Finally, the SCOPE study (Lithell et al 2003) has evalu-
ated the effect of an angiotensin receptor blocker ± diuretic 
on the cognitive function of 4964 elderly (70–89 years) hyper-
tensive patients without dementia. After 3.7 years of follow 
up, no signiﬁ  cant difference between the two groups was 
found for cognitive function and dementia. However, this lack 
of beneﬁ  t could probably be attributed to the fact that most 
patients in the placebo group were treated with other antihy-
pertensive drugs for ethical reasons. Moreover, the cognitive 
evaluation was based solely on the MMSE (Mini Mental 
State Examination) which lacks the sensitivity to detect a 
Table 2 Effect of antihypertensive drugs on cognitive decline or dementia in randomised, placebo-controlled studies
Studies na ∆SBP/DBP Drugs Follow up Outcomes
(active - placebo)
MRC 2584 −15.8/5 mmHg BB or Diu 54 months Non-signiﬁ  cant effect
on cognitive function
SHEP 4736 −12/4 mmHg BB ± Diu 4.5 years Reduction of dementia 16% 
(non signiﬁ  cant)
SYST-EUR 2418 −8.3/3.8 mmHg CCB ± ACEI ± Diu 2 years Reduction of dementia 50% 
(0 to 76%)
SYST-EUR 2 (open 
follow up)
2902 –7/3.2 mmHg CCB ± ACEI ± Diu ± others 4 years Reduction of dementia 55% 
(24%–73%)
PROGRESS 6105 −9/4 mmHg ACEI ± Diu 4 years Reduction of cognitive 
decline 19% (4%–32%) 
Reduction of dementia 
with recurrent stroke: 34% 
(3%–55%)
HOPE 9297 −3.8/2.8 mmHg ACEI 4.5 years Reduction of cognitive 
decline related to stroke 41% 
(6%–63%)
SCOPE 4964 −3.2/1.6 mmHg ARB ± Diu 3.7 years Reduction of dementia 7% 
(non signiﬁ  cant)
an = numbers of subjects at inclusion.
Abbreviations:   ACEI, angiotensin converting enzyme inhibitors;   ARB, angiotensin receptor blockers; BB, beta blockers; CCB, calcium channel blockers; Diu, diuretics.Vascular Health and Risk Management 2008:4(2) 367
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slight cognitive decline in subjects without dementia. Lastly, 
a recent analysis of SCOPE (Skoog et al 2005) has indicated 
a signiﬁ  cant reduction of cognitive decline in the subgroup 
of subjects with already low cognitive function at baseline 
(MMSE score between 24 and 28), whereas no beneﬁ  t was 
observed in people with normal cognitive function.
Some recent meta-analyses concerning these random-
ized, placebo-controlled studies were able to give a more 
complete picture of the effects of antihypertensive treatments 
on cognition. Some of them have supported a beneﬁ  t of anti-
hypertensive treatments for preventing dementia (Feigin et al 
2005; Birkenhager and Staessen 2006) or cognitive disorders 
(Birns et al 2006).
Alternatively, the Cochrane review concluded that blood 
pressure reduction resulted in an 11% reduction in the relative 
risk of dementia in patients with no prior cerebrovascular dis-
ease, but this effect was not statistically signiﬁ  cant (p = 0.38). 
Nevertheless, this review takes into account only 3 studies 
(SCOPE, SHEP, and SYST-EUR) which could minimize the 
effects of antihypertensive therapy (McGuiness et al 2006).
There are multiple underlying pathophysiological mecha-
nisms that could give an explanation for the association 
between hypertension and dementia.
Data from histopathological studies indicate a major 
overlap between vascular lesions and AD (Arregui et al 
1982; Victoroff et al 1995; Snowdon et al 1997). By promot-
ing arteriosclerosis and lipohyalinosis of the small vessels, 
hypertension might be the origin of stroke and/or chronic 
hypoperfusion of the white matter, thus contributing to the 
early expression of a still subclinical AD. It has been shown 
that patients with high midlife systolic blood pressure (SBP) 
experience cognitive dysfunctions as well as increased vol-
ume of white matter hyperintensities in late life (Swan et al 
1998a,b). A signiﬁ  cant interaction between hypertension, 
ApoE ε4 allele and white matter lesions has been found 
(de Leeuw et al 2004). It is also pointed out that the progression 
of the white matter lesions is highly correlated with cognitive 
decline. Furthermore, longitudinal studies found an increased 
risk of AD in people with periventricular white matter lesions 
(Prinds et al 2004). In this way, a very recent study found 
that white matter hyperintensities on magnetic resonance 
imaging scan, were signiﬁ  cantly associated with cognitive 
decline in MCI patients (mean follow-up = 3.8 ± 1.6 years) 
(Debette et al 2007). Moreover, antihypertensive therapy 
has been showed to reduce white matter lesions progression 
in a longitudinal study including patients with a history of 
stroke (Dufouil et al 2005a). In this way, such presence of 
cerebral white matter lesions could be an indication for early 
neuroprotection. Microcirculation disorders and endothelial 
dysfunctions are also given as explanations for the cognitive 
impairment seen in hypertensive subjects. Hypertension is 
associated with degenerative changes of intracerebral capil-
laries and arterioles and ADis associated with lesions in the 
cerebral microvasculature (Perlmutter et al 1991). These 
vessel changes may compromise the function of the blood-
brain barrier, leading to an increased vascular permeability 
and protein extravasation into the brain parenchyma, resulting 
in beta-amyloid accumulation (Hardy et al 1986). Likewise, 
hypertension and beta amyloid act on endothelial cells to 
produce an excess of free radicals suggesting that oxidative 
stress is involved in the mechanisms of both vascular dis-
orders and AD. Finally, periods of hypotension, hypoperfu-
sion and hypoxia, observed in hypertensive subjects, might 
contribute to cognitive deﬁ  cits in AD patients via reduced 
cerebral perfusion causing ischemic neuronal lesions in 
vulnerable areas of the brain.
In summary, hypertension may impair cognitive functions 
and is related to the occurrence of not only vascular dementia 
but also AD. Randomized, placebo-controlled trials have 
demonstrated that blood pressure-reducing agents decrease the 
incidence of dementia in stroke patients (PROGRESS, HOPE) 
and in elderly patients with isolated systolic hypertension 
(SYST-EUR), but this was not found in SCOPE and SHEP.
In this context, the incidence of dementia should be a 
major outcome measure of future trials comparing different 
antihypertensive drugs.
Diabetus mellitus and cognitive 
decline
Type 2 diabetus mellitus (DM) is a common disease in the 
elderly affecting more than 10% of the elderly population 
in the US, and its prevalence increases with age (Harris 
1998).
A possible relationship between cognitive decline and 
diabetes has been suggested since the discovery of insulin 
(Miles and Root 1922). A review of 33 longitudinal studies 
found that, in patients with type 1 diabetus mellitus, cogni-
tive dysfunction was characterized by a slowing of mental 
speed and diminished mental ﬂ  exibility, whereas learning 
and memory were spared (Brands et al 2005).
Several longitudinal studies have shown a relationship 
between type 2 DM and accelerated cognitive decline (Allen 
et al 2004). The results of the Atherosclerosis Risk In Com-
munities study (ARIC) were of particular interest because 
of an adjustment used for confounding cardiovascular fac-
tors (Knopman et al 2001). In this study of 10,963 middle Vascular Health and Risk Management 2008:4(2) 368
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aged people followed over 6 years, there was a signiﬁ  cant 
association between type 2 DM and decline in sustained atten-
tion, psychomotor speed and logical reasoning as well as in 
verbal learning and recent memory. Moreover, in the same 
cohort, insulin resistance appeared to be a midlife risk factor 
for cognitive decline and dementia (Young et al 2006).
A review by Allen et al (2004) put forward several 
limitations of these large longitudinal studies: Their 
vulnerability to survivor bias, the importance of confounding 
factors, their failure to record the duration of DM and 
the difficulty in choosing and conducting appropriate 
psychometric tests. More recently, a longitudinal study 
(Luschinger et al 2007) including 918 participants (mean 
age = 75.9 years ± 6), with a mean follow-up of 6.1 ± 3.2 
years per person, disclosed that DM was related to a higher 
risk of memory impairment (HR = 1.5; 95% CI = 1.0–2.2; 
p = 0.02 after adjusting for vascular risk factors). Globally, 
people with type 2 DM were at increased risk for developing 
cognitive impairment in comparison with the general 
population (Allen et al 2004).
Although type 2 DM is a well-established risk factor for 
stroke (Stegmayer and Asplund 1995), conﬂ  icting results have 
been reported about its association with dementia, especially 
AD. Cross sectional studies have suggested an association 
between type 2 DM and dementia (Janson et al 2004), but 
only longitudinal population-based studies can robustly asses 
the risk of developing dementia ascribable to DM.
Several studies have been designed with this aim and 
most of them have been included in a review by Biessels 
et al (Biessels et al 2006).
Four studies (Table 3) assessed the relationship between 
DM in midlife and dementia later in life. The Honolulu Asian 
Study initially failed to ﬁ  nd a positive association between 
DM and Alzheimer Disease (Curb et al 1999). Subsequent 
follow-up surveys in the same cohort disclosed a different 
result (Peila et al 2002) which was consistent with neuro-
pathological data: DM was associated with an increased risk 
for total dementia, AD, and VaD. This result was conﬁ  rmed 
by the Japanese Adult Health Study (Yamada et al 2003). 
Similarly, 2 other long-term follow-up studies highlighted the 
link between DM and dementia (Schnaider Beeri et al 2004; 
Whitmer et al 2005). Nevertheless, these types of studies are 
particularly sensitive to survivor bias.
Studies in which DM is assessed late in life show a fairly 
consistent association between DM and dementia (Table 3) 
(Ott et al 1999; Luchsinger et al 2001; Hassing et al 2002; 
MacKnight et al 2002; Arvanitakis et al 2004; Xu et al 2004; 
Luchsinger et al 2005).
The conclusion of Biessels et al was that, overall, the 
incidence of dementia was increased by 50%–100% in people 
with DM relative to those without diabetes. The increased risk 
included both AD and VaD (Biessels et al 2006). Furthermore, 
a longitudinal study of 1177 subjects older than 75 years old, 
followed over 9 years, recently disclosed an association between 
borderline diabetes and dementia (1.67; 95% CI (1.04–2.67)) 
and AD (1.77; 95% CI (1.06–2.97)). This was independent of 
future development of DM, giving a great importance to the 
link between hyperglycemia and dementia (Xu et al 2007). 
Similarly, an association was found between glycosylated 
hemoglobin levels (HbA1c) and the risk of developing memory 
impairment or dementia in 1938 postmenopausal, osteoporotic 
women followed over 4 years. For every 1% increase in HbA1c, 
these women had a greater age-adjusted likelihood of develop-
ing mild cognitive impairment or dementia (OR = 1.40; 95% 
CI = 1.08–1.83) (Yaffe et al 2006).
One major modulatory factor in these studies was that DM 
was frequently associated with co-morbid conditions that are 
known to play a role in cognitive decline, such as hyperten-
sion and hypercholesterolemia. These co-morbid conditions 
could be important determinants of the increased risk of 
dementia in people with DM. Several studies provided results 
adjusted for cardiovascular disease. Two studies reported 
that adjusting for vascular risks factors did not change the 
results of univariate analysis (MacKnight et al 2002; Peila 
et al 2002) for all dementia subtypes. On the other hand, the 
Kungsholmen study found that systolic hypertension and 
diabetes combined to modify the relative risk of dementia 
when considering AD and VaD (Xu et al 2004).
Furthermore, ApoE genotype may be an important 
confounding factor. Two studies found out that Apo E ε4 
genotype combined with DM doubled the relative risk of 
dementia compared with DM alone (Peila et al 2002; Xu 
et al 2004). More recently, results of the Framingham Study 
pointed out that DM did not increase the risk of AD overall. 
After adjusting for the ApoE ε4 allele or elevated plasma 
homocysteine levels, however DM appeared as a risk fac-
tor for AD (Akomolafe et al 2006). DM, then, was a strong 
independent risk factor for AD among people at a relatively 
lower initial risk for developing the disease. In conclusion, 
longitudinal studies now provide evidence that DM is a risk 
factor for cognitive decline and dementia (AD and VaD), but 
the pathophysiological mechanisms underlying this associa-
tion are still unknown.
Brain autopsy studies may provide information about 
these underlying mechanisms. First, DM is associated with 
brain infarcts and pathological changes in the cerebral Vascular Health and Risk Management 2008:4(2) 369
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microvasculature including amyloid angiopathy (Peila et al 
2002). Furthermore, 216 autopsies from the Honolulu-Asia 
Aging Study showed that participants with type 2 DM and 
the ApoE ε4 allele had a higher number of neuritic plaques 
in the hippocampus and neuroﬁ  brillary tangles in the cortex 
and hippocampus (Peila et al 2002).
Three main pathological mechanisms are proposed to 
explain the link between DM and dementia (Biessels et al 
2006; Qiu and Folstein 2006).
First, DM may lead to dementia through ischemic cere-
brovascular disease. DM, especially in elderly people, often 
develops in a cluster of vascular risk factors which can con-
stitute the metabolic syndrome, which is already known to 
be predictor of cerebrovascular disease (Kalmijn et al 2000; 
Yaffe et al 2004).
Second, hyperglycemia can have a direct toxic effect on 
neurons by causing oxidative stress and the accumulation of 
advanced glycation end products, a process which can directly 
affect brain tissue, and also lead to microvascular changes 
(Kumari et al 2000). Lastly, insulin and insulin-degrading 
enzymes could play an important role in amyloid metabo-
lism (Qiu and Folstein 2006). Insulin resistance, at least in 
Table 3 Risk of incident dementia in patients with Diabetus mellitus in longitudinal studies
Dementia na Follow-up (years) Ageb Outcomes
Any dementia
Peila, 2002 3508 2.9 77 Positive correlation. RR (95% CI) = 1.5 (1.0–2.2)
Adjusted RRc (95% CI) = 1.5 (1.0–2.2)
Whitmer 2005 8845 35 42 Positive correlation. RR (95% CI) = 1.5 (1.2–1.8)
Schnaider Berri 2004 10059 35 45 Positive correlation. RR (95% CI) = 2.8 (1.4–5.7)
Ott 1999 6370 2.1 69 Positive correlation. RR (95% CI) = 1.9 (1.3–2.8)
Xu 2004 1301 4.7 81 Positive correlation. RR (95% CI) = 1.5 (1.1–2.1)
Adjusted RR (95% CI) = 1.5 (1.0–2.1)
Curb 1999 3774 25 53 Non signiﬁ  cant correlation. RR (95% CI) = 1.1 (0.7–1.8)
Hassing 2002 702 6 84 Non signiﬁ  cant correlation.   Adjusted RR (95% CI) = 1.2 (0.8–1.7)
MacKnight 2002 9131 5 74 Non signiﬁ  cant correlation. RR (95% CI) = 1.2 (0.9–1.7)
Adjusted RR (95% CI) = 1.3 (0.9–1.8)
AD
Peila 2002 3508 2.9 77 Positive correlation. RR (95% CI) = 1.7 (1.0–2.8)
Yamada 2003 1774 30 43 Positive correlation. RR = 4.4
Akomolafe 2006 2210 12.7 70 Positive correlation.   Adjusted RR (95% CI) = 2.98 (1.06–8.9)
Ott 1999 6370 2.1 69 Positive correlation. RR (95% CI) = 1.9 (1.2–3.1)
Luchsinger 2001 1799 4.3 76 Positive correlation. RR (95% CI) = 2.4 (1.8–3.2)
Adjusted RR (95% CI) = 2.0 (1.4–2.9)
Arvanitakis 2004 847 5.5 75 Positive correlation. RR (95% CI) = 1.7 (1.1–2.5)
Xu 2004 1301 4.7 81 No signiﬁ  cant correlation. RR (95% CI) = 1.3 (0.8–1.9)
Adjusted RR (95% CI) = 1.3 (0.9–2.1)
Luchsinger 2005 1786 5.5 76 Positive correlation. RR (95% CI) = 2.4 (1.8–3.2)
Adjusted RR (95% CI) = 2.0 (1.4–2.9)
Curb 1999 3774 25 53 Non signiﬁ  cant correlation. RR (95% CI) = 1.0 (0.5–2)
Hassing 2002 702 6 84 Non signiﬁ  cant correlation. Adjusted RR (95% CI) = 0.8 (0.5–1.5)
MacKnight 2002 9131 5 74 Non signiﬁ  cant correlation. RR (95% CI) = 1.2 (0.8–1.8)
Adjusted RR (95% CI) = 1.3 (0.8–2.0)
VaD
Peila 2002 3508 2.9 77 Positive correlation
RR (95% CI) = 2.2 (1.1–4.7)
Adjusted RR (95% CI) = 2.3 (1.1–5.0)
Yamada 2003 1774 30 43 Positive correlation. RR = 1.3 (p = 0.06)
Ott 1999 6370 2.1 69 Positive correlation. RR (95% CI) = 2.0 (1.7–5.6)
Luchsinger, 2001 1799 4.3 76 Positive correlation. RR (95% CI) = 4.2 (2.2–8.3)
Adjusted RR (95% CI) = 3.4 (1.7–6.9)
Hassing 2002 702 6 84 Positive correlation. Adjusted RR (95% CI) = 2.5 (1.4–4.8)
MacKnight, 2002 9131 5 74 Positive correlation. RR (95% CI) = 2.2 (1.3–3.6)
Adjusted RR (95% CI) = 2.0 (1.2–3.6)
Xu 2004 1301 4.7 81 Positive correlation. RR (95% CI) = 2.2 (1.1–5.0)
Adjusted RR (95% CI) = 2.6 (1.2–6.1)
Curb 1999 3774 25 53 Non signiﬁ  cant correlation. RR (95% CI) = 1.5 (0.8–2.8)
a= numbers of subjects at inclusion.
bat baseline.
cRR adjusted for vascular risk factors.
Abbreviations: AD, Alzheimer’s disease; RR, relative risk; VaD, vascular dementia.Vascular Health and Risk Management 2008:4(2) 370
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the early stages of DM, is associated with compensatory 
hyperinsulinemia and hyperinsulinemia even in the absence 
of diabetes and is strongly associated with AD (Luschinger 
et al 2004). Insulin receptors are distributed with particular 
abundance in the hippocampus and cortex (Bondy and 
Cheng 2004). Insulin appears to stimulate amyloid β secre-
tion and inhibits the extrascellular degradation of amyloid β 
(Gasparini and Xu 2003) by competing for insulin degrading 
enzyme which may be deﬁ  cient (Qiu and Folstein 2006).
These data offer avenues to the prevention of dementia.
Considering longitudinal studies, strict control of DM 
seems to be an important goal in order to prevent subsequent 
dementia. However, the impact of intensive glucose-lowering 
treatments on the incidence of dementia is still unknown. 
The ADVANCE study will give some answers, as dementia 
is being considered as a secondary outcome (Rationale and 
design of the ADVANCE Study 2001).
In consideration of the underlying pathological mecha-
nisms, researches are being conducted with treatments for 
insulin resistance such as Rosiglitazone® (Hsueh 2006) and 
gene therapy targeting insulin degrading enzyme (Qiu and 
Folstein 2006).
Adiposity, metabolic syndrome 
and cognitive decline
Obesity affects 25%–30% of adults in industrialised countries 
(Rennie and Jebb 2005). In the past, studies reported that a 
low body mass index (BMI) was a risk factor for dementia 
(White et al 1996). However, these observations were based 
on cross-sectional studies, and with dementia, previously 
obese patients may lose up to 50% of their predementia 
body weight (Wang 2002). As rewieved by Gorospe and 
Dave (2007) and Gustafson (2006), epidemiological studies 
of increased BMI as a risk factor for dementia have shown 
conﬂ  icting results. Nevertheless, the studies with statistically 
signiﬁ  cant results had larger sample sizes, longer follow-up 
periods and younger participants at baseline (Gorospe and 
Dave 2007). Thus, a 27-year longitudinal, population-based 
study of 10,276 subjects showed that people with a high BMI 
had a signiﬁ  cant higher risk of dementia (HR = 1.74; 95% CI = 
1.35–1.24) after adjusting with vascular comorbidities and 
socioeconomic status (Whitmer et al 2005). Similarly, a study, 
that followed participants over 18 years, concluded that for 
every 1.0 increase in BMI at 70 years old, AD risk increased 
by 36% after adjusting with vascular confounding factors 
(Gustafson et al 2003). Two other well-designed and powerful 
studies found similar results (Kalmijn et al 2000; Rosengreen 
et al 2005). More recently a 36-year longitudinal study of a 
large cohort (n = 10,136) found that people who were obese at 
midlife (BMI   30) had a 3.10-fold increased risk of AD (HR = 
3.10; 95% CI = 2.19–4.38) and a 5-fold increased in risk of 
Vad (HR = 5.01; 95% CI = 2.98–8.43), while those who were 
overweight (BMI   25) had a 2-fold increased risk of AD and 
Vad (HR = 2.09; 95% CI = 1.69–2.60 for Alzheimer disease 
and HR = 1.95; 95% CI = 1.29–2.96 for vascular dementia), 
independent of vascular comorbidities (Whitmer 2007). All 
these results suggest that an increased BMI is likely to be an 
important risk factor for dementia, even though there are no 
published reports that take into account the role of ApoE ε4.
As for DM, excess adiposity could increase the risk of 
dementia by a vascular pathway (Gustafson 2006). Further-
more, adipose tissue secretes adipocytokines such as leptin 
which may be involved in neurodegenerative pathways 
(Benoit et al 2004).
For now, then, an elevated BMI in middle age appears to 
be an important risk factor for dementia, and the maintenance 
of a normal weight could be a worthwhile intervention for the 
prevention of dementia (Gorospe and Dave 2007).
The metabolic syndrome is a cluster of cardiovascular 
risk factors including obesity. In most studies, it is deﬁ  ned 
using the National Education Program Third Adult Treatment 
Panel Guide (Expert Panel 2001). It has been proven to be 
associated with an increased risk of developing cardiovas-
cular disease (Expert Panel 2001). It is also an independent 
risk factor for silent brain infarctions on magnetic resonance 
Imaging in middle age, healthy people (Kwon et al 2006).
Few studies have considered the components of the 
metabolic syndrome as a whole, whereas several individual 
components have been linked to risk of developing dementia 
and cognitive impairment. Furthermore, it is unclear whether 
the metabolic syndrome has a higher predictive value for 
the development of dementia than the sum of its individual 
components (Yaffe 2007).
Some transversal studies have shown a link between 
metabolic syndrome and cognitive impairment. A popula-
tion-based study of 959 subjects (range 69 and 78 years old), 
found that metabolic syndrome was signiﬁ  cantly associated 
with AD (OR = 2.46; 95% CI = 1.27–4.78) (Vanhanen 
et al 2006). In addition, a cross-sectional study of the 1183 
participants of the Longitudinal Aging Study Amsterdam 
showed that metabolic syndrome was associated to poorer 
cognitive functioning (Dik et al 2007). Lastly, a very recent 
case control study, showed that the metabolic syndrome was 
associated with AD (OR = 3.2, 95% CI = 1.2–8.4, p = 0.02) 
(Razay et al 2007). This association was strengthened when 
the hypertension component was excluded.Vascular Health and Risk Management 2008:4(2) 371
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A few studies with a longitudinal design have been 
conducted. First, in the Honolulu-Asia Aging study, the long 
term association between clustered metabolic cardiovascu-
lar risk factors in the middle age and the risk of dementia 
in old age was assessed. Z scores were calculated for 7 
cardiovascular risk factors. The z-score sum was higher in 
subjects with dementia than in subjects without dementia 
(0.74 versus –0.06 respectively; p = 0.008). Per SD increase 
in the z-score sum, the risk of dementia was increased by 5% 
(RR = 1.05, 95% CI = 1.02–1.09). Considering the subtypes 
of dementia, signiﬁ  cance was maintained only for vascular 
dementia (RR = 1.11, 95% CI = 1.05–1.18) (Kalmijn et al 
2000). Furthermore, the Health Aging and Body Composi-
tion study assessed the cognitive abilities of 2,949 elderly 
subjects at baseline, 3 and 5 years by the Modiﬁ  ed MMSE, 
and found that metabolic syndrome was associated with a 
greater likelihood of cognitive decline (OR = 1.21; 95% CI = 
1.03–1.43) (Yaffe et al 2004). Similarly, the Sacramento Area 
Latino Study of Aging enrolled 1624 elderly Latinos sub-
jects, who were cognitively evaluated yearly over three years 
by the Modiﬁ  ed MMSE and the Delayed Word-List recall 
from the Spanish – English verbal learning test. Subjects 
with metabolic syndrome scored lower than those without 
metabolic syndrome on the Modiﬁ  ed MMSE (p = 0.04), but 
the difference between the two groups on the Delayed Word – 
List recall was no longer signiﬁ  cant (p = 0.18) (Yaffe et al 
2007). These two last studies also found that the composite 
measure of metabolic syndrome was a greater risk for cogni-
tive decline than its individual components.
Thus, metabolic syndrome seems to be a risk factor (Yaffe 
et al 2007) for cognitive decline, even though further long 
term prospective studies have to be conducted.
Mechanisms linking metabolic syndrome to cognition 
remain speculative (Yaffe et al 2007). An association between 
metabolic syndrome and cognitive decline could be explained 
by vascular disease. As previously studied in diabetus mel-
litus, insulin resistance seems to play a key role. This associa-
tion could also be, a least partly, mediated by inﬂ  ammation 
(Yaffe et al 2007). Lastly, central adiposity is a core feature 
of metabolic syndrome, so adipocytokines could also play a 
role (Benoit et al 2004).
Cholesterol, statins, and cognitive 
decline
Several epidemiological studies have assessed the link 
between cholesterol levels and dementia, especially AD 
(Panza et al 2006). Cross-sectional studies provided very 
conﬂ  icting results. A Finnish study of 980 people between 
69 and 78 years old, found an association between low serum 
total cholesterol (TC) and AD, independent of ApoE genotype 
(OR = 0.69; 95% CI = 0.52–0.92, p = 0.011) (Kuusisto et al 
1997). Another cross-sectional study of 1449 elderly subjects 
showed that decreased TC had an inverse association with the 
incidence of AD, independent of ApoE genotype (RR = 1.6; 
95% CI = 1.0–2.7) (Romas et al 1999). The study of Evans 
et al found that high TC was associated with AD only in the 
group which lacked an ApoE 4 allele (OR = 1.018; p = 0.027) 
(Evans et al 2000). Lastly, the three City Study, a population-
based cohort of 9,294 subjects selected from electoral rolls, 
showed that higher TC ( 6.20 mmol/L) was associated with 
increased odds of dementia (p = 0.07) but not AD (Dufouil 
et al 2005 b).
Several more poverfull longitudinal studies have assessed 
the increased risk of dementia ascribable to high cholesterol 
levels. Their results are summarized in the Table 4.
Two studies showed an epidemiologic link between 
high cholesterol level and Vad (Moroney et al 1999; Reitz 
et al 2004). Nevertheless, the results of studies which have 
investigated the relationship between cholesterol levels 
and risk of AD or any dementia are conﬂ  icting (Table 4). 
Globally, when cholesterol level was assessed in the middle 
age, a positive association with AD was found (Notolka 
et al 1998; Kivipelto et al 2002) with the exception of the 
Honolulu Asia aging Study where a cluster of vascular risk 
factors was considered (Kalmijn et al 2000). On the other 
hand, when cholesterol levels were considered later in life, 
the association with AD appeared not to be signiﬁ  cant (Tan 
et al 2003; Reitz et al 2004). Furthermore, very recently, 
Mielke et al (2005), examined the association between cho-
lesterol level and dementia in a population-based cohort of 
70-year-old subjects followed over 18 years. Increasing TC 
levels at ages 70, 75, and 79 were associated with a reduced 
risk of dementia between age 79 and 88 (Table 4). The same 
discrepancy was found for studies investigating the relation-
ship between cholesterol and MCI. In a the study by Solfrizzi 
et al (Solfrizzi et al 2004b) of 2936 subjects between 65 and 
84 years old followed over 3.5 years, multivariate analysis 
suggested that higher levels of serum TC had a trend for 
protective effect.Conversly, Kivipelto et al found that elevated 
serum TC levels ( 6.5 mmol/L) in middle age increased the 
risk for MCI (OR = 2.1; 95% CI = 1.2–3.0) with an average 
follow-up of 21 years (Kivipelto et al 2001).
These surprising results may be explained by the tim-
ing of TC measurements in relation to age and clinical 
onset of dementia. Indeed, these different ﬁ  ndings may 
be due to the fact that total cholesterol decreases with age Vascular Health and Risk Management 2008:4(2) 372
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(Postglione et al 1989) and insufﬁ  cient nutrition, and that, 
several years before dementia, blood pressure and BMI begin 
to decline, possibly as a result of the ongoing AD pathology, 
suggesting that the same may be true for TC (Panza et al 
2006). Decreased cholesterol might be an effect rather than 
a cause of dementia.
The few studies that have investigated the inﬂ  uence of 
ApoE genotype on the relationship between plasma lipid 
levels and dementia risk has given conﬂ  icting results (Notolka 
et al 1998; Evans et al 2000; Kivipelto et al 2002). Neverthe-
less, TC levels may be inﬂ  uenced by ApoE genotype (Notolka 
et al 1998; Evans et al 2000).
The pathophysiological mechanisms linking cholesterol 
metabolism to AD are still unknown (Wolozin 2004; Shobab 
et al 2005; Panza et al 2006). Cholesterol inﬂ  uences the activ-
ity of the enzymes involved in the metabolism of the amyloid 
precursor protein and in the production of Aβ. Some in vitro 
studies have shown that a high cholesterol level results in 
reduced production of soluble amyloid precursor protein 
(Racchi et al 1997; Simons et al 1998) and that cholesterol 
modulates α-secretease cleavage of amyloid precursor protein 
production (Bodovitz and Klein 1996).This implicates the 
amyloid cascade leading to neuronal death. The mechanism by 
wich cholesterol affects Aβ production and metabolism is not 
fully understood, a change in membrane properties has been 
suggested (Shobab et al 2005). However, cholesterol could 
have several beneﬁ  cial effects as well. Cholesterol forms an 
essential component of cell membranes and has a crucial role 
in neuronal plasticity (Pfrieger 2003). In addition, in vitro stud-
ies have suggested that cholesterol acts as an antioxidant and, 
therefore, has a protective role in dementia pathogenesis.
The relationship between cholesterol and AD is not clear 
and at times, is even, contradictory. Epidemiological studies 
have shown mixed results depending on if TC was assessed in 
middle age or later in life. A high cholesterol level in middle 
age seems to be a risk factor for AD, but this positive relation-
ship is not seen in late life (Panza et al 2006). Furthermore, 
pathophysiological data are also confusing. Given that the tim-
ing of exposure may be critical, more studies with long-term 
follow-up and serial assessments of  TC are needed to clarify the 
causal relationship between cholesterol and dementia. Lastly, 
some studies have been performed to asses the link between 
other lipids and cognitive decline. First, the 24S-hydroxycho-
lesterol, an oxidized metabolite of cholesterol which crosses the 
blood-brain-barrier, reﬂ  ects brain cholesterol homeostasis more 
than plasma TC (Shobab et al 2005). During the early stages 
of AD, 24S-hydroxycholesterol concentrations are high in 
cerebro- spinal ﬂ  uid and in peripherical circulation potentially 
reﬂ  ecting increased cholesterol turnover in the brain (Lutjohann 
et al 2000; Papassotiropoulos et al 2000; Kolsh et al 2004). 
However, in later stages of AD, concentrations of 24S-hydroxy-
cholesterol fall, suggesting that there is a low rate of cholesterol 
transport as the disease progresses (Kolsh et al 2004). Thus, 
24S-hydroxycholesterol might be a biochemical marker of 
worsening cognitive function in AD. Second, lipoprotein (a) 
(Lp(a)) is a LDL-like particle. High Lp(a) levels are associ-
ated with atherosclerosis (Milionis et al 2000). Some studies 
provide evidence that higher Lp(a) level could be linked with 
AD (Mooser et al 2000; Solfrizzi et al 2002a). Nevertheless, 
larger clinical studies involving MCI patients and longitudinal 
studies of AD patients are needed to conﬁ  rm the relationship 
between Lp(a) concentrations and dementia.
Table 4 Association between cholesterol level and dementiain longitudinal studies
Reference na (baseline) Age at baseline  Follow-up  Outcomes
(years) (years)
Notkola 1998 444 40–59 30 Positive correlation between TC and AD
RR (95% CI = 3.1(1.2–8.5)
Kivipelto 2002 1449 53 21 Positive correlation between TC and AD
RR (95% CI) = 2.8 (1.2–6.7)
Moroney 1999 111 75 7 Positive correlation between LDL-C and AD
RR (95% CI) = 3.1 (1.5–6.1)
Kalmijn 2000 8006 52.7 26 Non signiﬁ  cant correlation between TC and any 
dementia RR (95% CI) = 1.10 (0.95–1.26)
Tan 2003 1026 76 8 Non signiﬁ  cant correlation between TC and AD
RR (95% CI) = 0.97 (0.90–1.05)
Reitz 2004 2820 78 4.8 Non signiﬁ  cant between LDL-C and AD
RR (95% CI) = 0.48 (0.26–0.86)
Mielke 2005 392 70 18 Negative correlation between TC and any 
dementia RR (95% CI) = 0.31 (0.11–0.85)
an = numbers of subjects at inclusion.
Abbreviations:   AD, Alzheimer’s disease; LDL-C, LDL-cholesterol; RR, relative risk; TC, total cholesterol.Vascular Health and Risk Management 2008:4(2) 373
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Statins are a ﬁ  rst line treatment for hypercholesterolemia 
and secondary prevention of cardio-vascular disease. A large 
observational study in three hospitals in the US found that the 
prevalence of probable AD in the cohort taking statins was 
60%–73% (p   0.001) lower than in the total patient popula-
tion or when compared with patients taking other medications 
typically used in the treatment of hypertension or cardio-
vascular disease (Wolozin et al 2000). This was conﬁ  rmed 
by other cross-sectional studies (Table 5) (Jick et al 2000; 
Hajjar et al 2002; Zamrini et al 2004; Dufouil et al 2005b). 
Nevertheless, all these studies were limited by an important 
indication bias since statins may have been prescribed less 
frequently in people with dementia. Conversly, the Cache 
County Study included 5092 elderly subjects, followed over 
3 years, and found no association between statin use and sub-
sequent onset of dementia or AD (Zandi et al 2005). However, 
in a study with longer follow-up (7 years) which included 344 
elderly subjects (mean age = 74), statin use was associated 
with a slight reduction in cognitive decline as assessed by 
the Modiﬁ  ed MMSE (Bernick et al 2005).
On the other hand, 2 large randomized studies do not 
support a protective effect of statins against dementia. The 
PROSPER study assessing the beneﬁ  ts of pravastatine versus 
placebo in 70- to 82-year-old subjects followed over 3 years, 
did not ﬁ  nd any signiﬁ  cant effects of this lipid lowering agent 
on cognitive performance (Shepherd et al 2002). Neverthe-
less, this result could be explained by an insufﬁ  cient length 
of follow-up. Furthermore, cognitive decline was assessed 
as a secondary endpoint in the Heart Protection Study, which 
included 20,536 patients, randomized to receive either 40 mg 
daily of simvastatin or a matching placebo. No statistical 
difference was found, but dementia was assessed by a phone 
interview, which may have been an important limitation 
(Heart Protection Study Collaborative Group 2002).
Interstingly, a recent pilot double blinded study of 63 AD 
subjects compared atorvastatine versus placebo, and found 
a beneﬁ  cial effect of the statin at 6 months as measured by 
the Alzheimer’s Disease Assessment Scale-cognitive Sub-
scale (p   0.03) and a trend towards a signiﬁ  cant beneﬁ  t at 
12 months (p = 0.055) (Sparks et al 2005). In this context 
longer trials testing statins on AD patients are ongoing.
All studies concerning statins and cognitive decline have 
a pathophysiological rationale. Statins inhibits HMG-CoA 
reductase, a key enzyme in the synthesis of cholesterol. 
Even though statins could be protective due to their choles-
terol-lowering effects, and their reduction of atherosclerotic 
plaque formation, it has been suggested that statins could 
have a more speciﬁ  c effect. Indeed, simvastatin has been 
shown to reduce the levels of Aβ 42 and Aβ 40 in vitro and 
in the brain of guinea pigs (Fassbender et al 2001). Moreover 
statins show a broad range of functions, such antioxidant 
activity, immunomodulation and regulation of inﬂ  ammatory 
processes which could prevent neuronal death.
The relationship between cholesterol and dementia var-
ies, depending on when the cholesterol is measured over the 
life course. Midlife high cholesterol level appears to be a 
risk factor for dementia, especially AD. Statins and AD are 
an attractive avenue of research, considering the putative 
preventive or curative role of statins. Further long-term, 
placebo controlled trials need to be conducted.
Atrial ﬁ  brillation and cognitive 
decline
Recently, there has been increasing evidence that AF may 
contribute to the development of cognitive dysfunction. Most 
of the data have been provided by observational studies.
First, in the Rotterdam study of 6584 subjects, a positive 
association was found between AF and dementia (OR = 2.3, 
95% CI = 1.4–3.7) or impaired cognitive functions (OR = 1.7, 
95% CI = 1.2–2.5). The strongest association was found not 
for Vad but rather for AD with cerebrovascular disease (OR = 
4.1, 95% CI = 1.7–9.7). An association was also present 
between AF and “pure” AD (OR = 1.8; 95% CI = 1.7–9.7) 
(Ott et al 1997).
Similarly, other cross-sectional studies have shown that 
AF is associated with cognitive dysfunction, independent of 
stroke or other cardiovascular risk factors. For example, a 
study by Kilander et al of 952 men between 69 and 75 years 
old found that the 44 men with AF had poorer cognitive 
functions when compared to those without AF as assessed by 
the MMSE and the Trail making test, independent of stroke 
(Kilander et al 1998b). This was conﬁ  rmed by a case-con-
trol study, which provided a complete cognitive assessment 
(O’Connell et al 1998) and another cross-sectional study 
(Sabatini et al 2000).
Very recent longitudinal studies have assessed the link 
between AF and dementia. First, a community-based cohort 
study (Miyasaka et al 2007) enroled 2837 subjects (mean 
age 71 ± 15 years) who were diagnosed with AF for the ﬁ  rst 
time and followed them for a median timeof 4.6 years, found 
a high Kaplan-Meier cumulative rate of dementia: 22.5 per 
1000 person-years whereas in the general population, the 
incidence of dementia was 6.8 per 1000 person-years (Edland 
et al 2002).
Similarly, the impact of AF on the conversion to dementia 
from a normal cognitive status (n = 431) or mild cognitive Vascular Health and Risk Management 2008:4(2) 374
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impairment (MCI) (n = 180), was studied in elderly patients, 
followed over an average of 4 and 3 years for subjects with 
normal cognitive status and MCI, respectively. AF was 
signiﬁ  cantly associated with conversion to dementia (HR = 
4.63, 95% CI = 1.72–12.46) in the MCI group, but not in the 
cognitively normal group (HR = 1.10; 95% CI = 0.40–3.03) 
(Forti et al 2007).
There are multiple possible mechanisms explaining 
the association between AF and risk of dementia. Throm-
boembolic damage and cerebral hypo perfusion due to 
ﬂ  uctuations in the cardiac output are involved (Sabatini 
et al 2000). Cerebrovascular disease is acknowledged to 
often coexist and overlap with AD and silent micro infarcts 
may markedly contribute to AD development (Kalaria 
2002). Therefore, it is possible that the brain damage as 
a result of AF plays a signiﬁ  cant role in the onset of AD 
because it brings neuronal function below a threshold 
where clinical symptoms begin to appear. Furthermore, 
experimental studies emphasises that ischemic insults or 
cerebrovascular insufﬁ  ciency lead to increased expression 
of amyloid precursor protein which leads to the formation 
of classic AD neurodegenerative lesions (Kalaria 2000; 
de la Torre 2006).
To conclude, there is some evidence that AF could 
be associated with AD. But there are not enough longi-
tudinal studies. Anticoagulation is the gold standard for 
treatment of AF in order to prevent stroke. Nevertheless, 
the ability of anticoagulation therapy to prevent or post-
pone dementia in cases of AD has not been studied yet. 
Aspirin is sometime an alternative therapy for AF when 
Table 5   Association between statin use and dementia or cognitive decline
Reference na Age (years) Population Type of study Outcomes
Jick 2000 1364  50 General population Cross sectionnal Association between statin and decreased 
risk of AD.
OR (95% CI) = 0.29 (0.13–0.63)
Hajjar 2002 655 79 Elderly subjects Cross sectionnal Association between statin and decreased 
risk of dementia.
OR (95% CI) = 0.23 (0.1–0.56)
Association between statin and decreased 
risk of AD.
OR (95% CI) = 0.37 (0.19–0.74)
Zamrini 2004 3397 70 Elderly subjects Cross sectionnal Association between statin and decreased 
risk of AD.
OR (95% CI) = 0.61 (0.42–0.87)
Dufouil-b 2005 8574 74 General population Cross sectionnal Association between statin and decreased 
risk of AD.
OR (95% CI) = 0. 56 (0.33–0.94)
Bernick 2005 334 74 Elderly subjects Longitudinal
(F up = 7 years)
Association between statin and slower 
cognitive decline
Masse 2005 342 73.5 AD Longitudinal
(F up = 34 months)
Association between statin use and slower 
cognitive decline
Zandi 2005 5092  65 Elderly subjects Longitudinal
(F up = 3 years)
No correlation between statin use and 
dementia
OR (95% CI) = 1.19(0.53–2.34)
No correlation between statin use and AD
Rea 2005 2798  65 years Elderly subjects with 
never use of lipid-lower-
ing agents
Longitudinal
(F up = 15,030
person – years)
No correlation between statin use and 
dementia
HR (95% CI) = 1.08 (0.77–1.52)
HPS 20536 40–80 High CV risk Randomized
Controlled trial
No correlation between statin use and 
cognitive function
(F up = 5 years)
PROSPER 5804 70–82 High CV risk Randomized
controlled trial
No correlation between statin use and 
cognitive function
(F up = 3.2 years)
an = numbers of subjects at inclusion.
Abbreviations: AD, Alzheimer’s disease; CV, Cardiovascular; F up, follow-up; HR, hazard ratio; OR, odds ratio; VaD, vascular dementia.Vascular Health and Risk Management 2008:4(2) 375
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anticoagulation can not be used. A longitudinal study 
(Nilsson et al 2003) of 702 elderly people found that those 
who used high doses aspirin had a significantly lower 
prevalence of AD than those who did not use aspirin, 
but Kang et al did not showed any benefit in prevention 
of cognitive decline for the 6377 women, included in the 
Women’s health study, after a 9.6 years follow-up (Kang 
et al 2007).
Smoking and cognitive decline
First, results from case-control studies have suggested that 
smoking could protect against AD (Graves et al 1991) sup-
porting a neuroprotective effect of the nicotine in cigarette 
smoke. On the other hand, smoking is a risk factor for 
atherosclerosis, cerebrovascular accidents and could cause 
vascular dementia (Shinton and Beevers 1989).
Recent prospective studies on cohorts without dementia 
suggest that smokers have a signiﬁ  cantly increased risk of 
dementia, including AD (Ott et al 1998; Launer et al 1999; 
Merchant et al 1999). The results of the Honolulu-Asia 
Aging Study (Tyas et al 2003) are of particular interest 
because of data collected about the amount of smoking, 
neuropathologic data and the long follow-up period. The 
association between midlife smoking and late-life dementia 
was assessed in 3734 Japanese-American men. Adjusting 
for age, education, and Apo E genotype, the risk of AD 
in smokers increased with pack-years of smoking at both 
medium (OR = 2.18; 95% CI = 1.07–4.69) and heavy (OR = 
2.40; 85% CI = 1.16–5.17) smoking levels. Neuropatho-
logic data were available for 218 men and in an autopsied 
sub-sample, the number of neuritic plaques increased with 
smoking level.
The effects of smoking on global cognitive function in 
elderly subjects without dementia were also assessed in a 
multi-center cohort including 9,209 subjects, 65 years old and 
over, who were followed up 2.3 years (Ott et al 2004). The 
average yearly decline in MMSE score was compared among 
groups, adjusting for age, sex, baseline MMSE, education, 
and stroke. The adjusted decline of former smokers was 0.03 
points greater than subjects who never smoked. For current 
smokers, this decline was 0.13 point greater than subjects 
who never smoked (p   0.001), suggesting that smoking 
may accelerate cognitive decline in elderly people without 
dementia.
Finally, a recent meta-analysis (Anstey et al 2007), of 19 
prospective studies with at least a 12-month follow-up period 
concluded that smokers at baseline, had risks of 1.79 (95% 
CI = 1.43–2.23) for incident AD, 1.78 (95% CI = 1.28–2.47) 
for incident Vad and 1.27 (95% CI = 1.02–1.60) for any 
dementia, relative to subjects who had never smoked. The 
authors concluded that elderly smokers have an increased 
risk of dementia and cognitive decline.
Smoking could affect cognition through various mecha-
nisms. First, chronic tobacco exposure causes atheroscle-
rosis which increase the risk of silent brain infarctions 
(Cruickshank et al 1989). Smoking may also be linked to 
AD by mechanisms leading to plaque formation. Smokers 
may experience greater oxidative stress than non-smokers 
and increased oxidative stress may cause neuronal degen-
eration (Markesbery 1997). Nevertheless, these underlying 
mechanisms are insufﬁ  ciently understood and require further 
experimental studies.
Atherosclerosis, coronary artery 
disease, heart failure, and cognitive 
decline
Atherosclerosis is believed to be involved in development 
of dementia and its major subtypes, vascular dementia 
and AD (de la Torre 2004). The association may be medi-
ated by cerebrovascular disease or result from brain hypo 
perfusion.
Indeed, there is some epidemiologic evidence for a 
relation between atherosclerosis and dementia risk. Accord-
ing to a cross-sectional report from the Rotterdam study 
(Hofman et al 1997), a strong association was found between 
atherosclerosis and dementia, especially AD (OR = 3.0; 
95% CI = 1.5–3.2). Furthermore, a very recent longitudinal 
study, including 6647 participants in the Rotterdam study 
with a mean follow-up of 9 years, disclosed that athero-
sclerosis (common carotid intima media thickness, carotid 
plaques, peripheral artery disease), predominantly carotid 
atherosclerosis, was associated with an increased risk for any 
type of dementia (van Oijen et al 2007). In the same way, a 
signiﬁ  cant relationship between aterial stiffness and cogni-
tive impairment has been showed (Hanon et al 2005a). This 
association has been recently conﬁ  rmed in a longitudinal 
study (Waldstein et al 2008).
These results suggest an independent relationship 
between atherosclerosis and AD (Casserly and Topol 2004). 
Indeed, the two diseases share common risks factors and 
pathophysiological elements. Hypercholesterolemia, oxyda-
tive stress and inﬂ  ammation have emerged as the dominant 
mechanisms in the development of both atherosclerosis 
and AD (Steinberg 2002). In the same way, the ε4 allele 
of the Apo E gene represents a genetic risk factor for ath-
erosclerosis (Wilson et al 1996) and the most important Vascular Health and Risk Management 2008:4(2) 376
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genetic risk factor for sporadic AD in the general population 
(Farrer et al 1997). Furthermore, vascular endothelial cells 
could play a role in the secretion of the precursor substrate 
of the neurotoxic A beta-protein leading to the destruction 
of cortical neurons in AD (Vagnucci and Li 2003). Likewise, 
endothelial lesions in AD have been related to the location 
and number of senile plaques (Kalaria and Hedera 1996) 
and it has been reported that beta amyloid could interact 
with vascular endothelial cells to produce an excess of free 
radicals (Thomas et al 1996).
Some investigations have shown the importance of 
inﬂ  ammation in the pathogenesis of AD (Akiyama et al 
2000). Fibrillar Aβ has been shown to directly activate the 
complement pathway in vitro. Furthermore, all the cytokines 
and chemokines seem to be upregulated in AD. The migcrog-
lia seems to be the most important cell mediator in the AD 
brain. Microglia cluster at sites of Aβ deposition and could 
play a role through the processing of APP and Aβ or in the 
conversion of nonﬁ  brillar Aβ into amyloid ﬁ  brils.
In this way ﬁ  ndings from observational studies have sup-
ported a treatment beneﬁ  t of low dose aspirin and non ste-
roidal anti-inﬂ  ammatory drugs in AD (Etminam et al 2003). 
However, results from a randomized study of the effects of a 
selective COX-2 inhibitor on disease progression have been 
negative (Reines et al 2004).
Moreover, coronary heart disease, one the major compli-
cations of atherosclerosis, has been associated with cognitive 
decline. In the cardiovascular health study cohort, includ-
ing 3602 subjects followed up 5.4 years, the incidence of 
dementia was higher in those with prevalent coronary artery 
disease. The rate of AD was 34.4 per 1000 person-years for 
subjects with coronary heart disease versus 22.2 per 1000 
person-years without coronary heart disease (HR = 1.3; 
95% CI = 1.0–1.7) (Newman et al 2005). Furthermore, a 
recent anatomopathological study disclosed that, coronary 
artery disease was associated with AD’s neuropathological 
hallmarks in APoE 4 carriers (Beeri et al 2006).
Congestive heart failure may also be an atherosclerosis’ 
complication and is a common medical condition among 
elderly people (Cowie et al 1997). Some studies have assessed 
the link between heart failure and cognitive impairment. It has 
been observed a higher prevalence of heart failure in people 
with cognitive disorders and the risk of cognitive impairment 
was 1.96-fold greater in subjects with chronic heart failure 
(CHF) (OR = 1.96; 95% CI = 1.07–3.58) compared to those 
without CHF (Cacciatore et al 1998). These results have been 
conﬁ  rmed in a large study including 13,635 patients show-
ing an increased prevalence of cognitive disorders among 
patients with heart failure (Zuccala et al 2001). Particularly, 
low blood pressure was signiﬁ  cantly associated with cogni-
tive impairment in patients with heart failure (Zuccala et al 
2001) suggesting the role of low cardiac output in cognitive 
dysfunction. Furthermore, in a 10-year prospective study, 
including 650 elderly people, cognitive decline was predicted 
by various vascular factors including heart failure (RR = 1.8) 
(Tilvis et al 2004).
Few studies have assessed a putative association between 
chronic heart failure and dementia.
A recent study addressed prospectively the relationship 
between heart failure and dementia among 1301 individuals 
75 years or older, with cognitive evaluation 3 times over a 
9-year period (Qiu et al 2006). Heart failure was associated 
with a multi-adjusted HR of 1.84 (95% CI: 1.35–2.51) for 
dementia and 1.80 (95% CI: 1.25–2.61) for AD. In this trial, 
heart failure and low diastolic blood pressure ( 70 mmHG) 
had an additive effect on the risk for developing dementia 
(HR = 3.07; 95% CI: 1.64–5.61). The potential biological 
pathways linking heart failure to cognitive impairment, 
dementia and AD are still unknown. First, heart failure is 
a risk factor for multiple cerebral emboli which could lead 
to cognitive impairment (Pullicino and Hart 2001). Second, 
low cardiac output may result in decreased cerebral perfusion 
which could play a part in the neurodegenerative process 
(Pullicino and Hart 2001). Prospective studies, concerning 
the effect of cardiac heart failure treatment need to be con-
ducted. In the study by Qiu et al it is suggested that the use of 
antihypertensive drugs (83% of which were diuretics) could 
reduce the risk of dementia related to heart failure (Qiu et al 
2006) and ACE inhibitors have been suggested to improve 
cognitive performance in patients with heart failure (Zuccala 
et al 2005). Nevertheless, some long-term prospective studies 
have to test this hypothesis
Conclusion
Vascular risk factors may impair cognitive functions and 
are related to the occurrence of not only Vad but also AD. 
This level of evidence for these associations is highest for 
hypertension and DM, especially when these factors are 
assessed in middle age. Furthermore, a dementia risk score, 
including age, sex, education, SBP, TC, physical activity 
and ApoE ε4 genotype, was recently proposed (Kivipelto 
et al 2006), but should be validated and further reﬁ  ned to 
increase its predictive value. Considering pathophysiological 
mechanisms, there are mechanistic studies that provide leads, 
but do not indicate which of these leads are clinically rel-
evant. Some studies have highlighted the possible protective Vascular Health and Risk Management 2008:4(2) 377
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effect of antihypertensive therapy on cognition and some 
trials are assessing the effects of statins and treatments for 
insulin-resistance. Considering that dementia is a worldwide 
problem, ﬁ  nding a preventive or curative treatment is a major 
health concern, and vascular risk factors are a promising 
avenue of research. Further long-term, placebo-controlled, 
randomized studies, need to be performed, eg, antihyper-
tensive therapy, statins, glitazones, antithrombotic agents 
versus placebo to slow down cognitive decline in MCI or 
AD populations even though in the absence of hypertension, 
hypercholesterolemia, and diabetus mellitus.
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